Hycamtin (Cervical Cancer) - Analysis and Forecasts to 2020

Hycamtin (Cervical Cancer) - Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Hycamtin (Cervical Cancer) - Analysis and Forecasts to 2020” provides Hycamtin sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2019). The report also includes information on Cervical Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the US and EU5
- Analysis and review of Hycamtin including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Hycamtin including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts for 2006-2019 for Hycamtin in the US and EU5

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Cervical Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 HPV Infections 6
2.3.2 Lack of Regular Papanicolaou (pap) Tests 6
2.3.3 Smoking 6
2.3.4 Sexual History 7
2.3.5 Birth Control Pills 7
2.4 GlobalData Pipeline Report Guidance 7
3 Cervical Cancer Disease: Market Characterization 8
3.1 Cervical Cancer Disease Market 8
3.2 Cervical Cancer Disease Market Forecasts and CAGR 8
3.3 Drivers and Barriers for the Cervical Cancer Market 8
3.3.1 Life Threatening Disease 9
3.3.2 Low Incidence 9
3.3.3 High Use of off-labeled drugs 9
3.3.4 Early Screening 9
3.3.5 Emergence of Vaccines 9
4 Tumor-Node-Metastases(TNM) Classification of Cervical Cancer 10
5 Hycamtin 13
5.1 Introduction 13
5.2 Mechanism of Action 13
5.3 Clinical Studies 13
Randomized Phase III Trial of cisplatin with or without topotecan in Carcinoma of the Uterine Cervix 13
5.4 Approval History of Hycamtin 14
5.5 Factors Affecting Sales of Hycamtin 14
5.5.1 Improved Efficacy 14
5.5.2 Novel Mechanism of Action 15
5.5.3 Generic Availability 15
5.5.4 Low Competition 15
5.6 Drug Evaluation 15
Drug Risk Benefit Score 15
5.6.1 Efficacy 16
5.6.2 Safety 16
5.6.3 Compliance 16
5.6.4 Dosing Convenience 16
5.7 Intensity of Competition 16
5.8 Sales forecast 17
5.8.1 Target patient Pool of Hycamtin 17
5.8.2 Dosing 17
5.8.3 Market Penetration 17
5.8.4 Annual Cost of Therapy 18
5.8.5 Sales Projections of Hycamtin 18
6 Cervical Cancer Market: Appendix 24
6.1 Market Definitions 24
6.2 Abbreviations 24
6.3 Research Methodology 24
6.3.1 Coverage 25
6.3.2 Secondary Research 25
6.3.3 Forecasting 25
6.3.4 Number of Patients Approved to take the Drug 25
6.3.5 Net Penetration of Drug 26
6.3.6 Net Annual Dosing 27
6.3.7 Annual Cost of Therapy 27
6.3.8 Primary Research 27
6.3.9 Expert Panels 27
6.4 Contact Us 28
6.5 Disclaimer 28
6.6 Sources 28